The effect of TIP on pneumovirus-induced pulmonary edema in mice

PLoS One. 2014 Jul 21;9(7):e102749. doi: 10.1371/journal.pone.0102749. eCollection 2014.

Abstract

Background: Pulmonary edema plays a pivotal role in the pathophysiology of respiratory syncytial virus (RSV)-induced respiratory failure. In this study we determined whether treatment with TIP (AP301), a synthetic cyclic peptide that mimics the lectin-like domain of human TNF, decreases pulmonary edema in a mouse model of severe human RSV infection. TIP is currently undergoing clinical trials as a therapy for pulmonary permeability edema and has been shown to decrease pulmonary edema in different lung injury models.

Methods: C57BL/6 mice were infected with pneumonia virus of mice (PVM) and received TIP or saline (control group) by intratracheal instillation on day five (early administration) or day seven (late administration) after infection. In a separate set of experiments the effect of multiple dose administration of TIP versus saline was tested. Pulmonary edema was determined by the lung wet-to-dry (W/D) weight ratio and was assessed at different time-points after the administration of TIP. Secondary outcomes included clinical scores and lung cellular response.

Results: TIP did not have an effect on pulmonary edema in different dose regimens at different time points during PVM infection. In addition, TIP administration did not affect clinical severity scores or lung cellular response.

Conclusion: In this murine model of severe RSV infection TIP did not affect pulmonary edema nor course of disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Humans
  • Male
  • Mice, Inbred C57BL
  • Murine pneumonia virus / drug effects
  • Murine pneumonia virus / isolation & purification*
  • Peptides, Cyclic / chemistry
  • Peptides, Cyclic / therapeutic use*
  • Pneumovirus Infections / complications
  • Pneumovirus Infections / drug therapy*
  • Pneumovirus Infections / pathology
  • Pulmonary Edema / drug therapy*
  • Pulmonary Edema / pathology
  • Pulmonary Edema / virology*
  • Respiratory Syncytial Virus Infections / complications
  • Respiratory Syncytial Virus Infections / drug therapy
  • Respiratory Syncytial Virus Infections / pathology
  • Respiratory Syncytial Viruses / drug effects
  • Respiratory Syncytial Viruses / isolation & purification
  • Tumor Necrosis Factor-alpha / chemistry

Substances

  • Peptides, Cyclic
  • Tumor Necrosis Factor-alpha
  • AP301 peptide

Grants and funding

The study was funded in part by APEPTICO GmbH, Vienna, Austria, which is the title holder of the TIP peptide AP301. Additional funding was received by the Janivo Foundation (reference 2011.063). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.